Company intelligence
Aiosyn
Achieve more perspective through precision pathology
About Aiosyn
Aiosyn is a Dutch healthtech company delivering AI-powered precision pathology solutions to enhance diagnosis and accelerate research in breast cancer and chronic kidney disease. Our algorithms integrate with existing digital pathology software and can be deployed via cloud-based or on-premise installations, ensuring adaptability to diverse laboratory environments. We support digital pathology labs with automated slide quality control (QC) and offer the first IVDR-certified AI solution for mitotic figure counting, improving consistency and efficiency in breast cancer grading. Our NephroPath platform enables quantitative kidney biomarker analysis for CROs and biopharma, helping streamline and scale (pre-)clinical drug development.
Verified activity
Signals from Aiosyn
6 published signals
Products & Services
Aiosyn launched a new website built around quantitative AI-based tissue analysis for preclinical studies and automated quality control for clinical laboratories.
Reported by Aiosyn
Products & Services
AiosynQC sits between the scanner and the pathologist to decide which slides are ready to read and which go back to the lab.
Reported by Patrick de Boer
Products & Services
Aiosyn launched a new website featuring a multi-organ suite for histology endpoints in preclinical studies.
Reported by Patrick de Boer
Products & Services
Aiosyn is building a multi-organ suite for histology endpoints in preclinical studies using algorithms that quantify tissue sections and return read-outs per preclinical model.
Reported by Patrick de Boer
Products & Services
Aiosyn has live histology endpoints including atherosclerosis, kidney, brain, and liver built with TNO, with more organs coming.
Reported by Patrick de Boer
Products & Services
Aiosyn launched a new website focusing on quantitative AI-based tissue analysis for preclinical studies and AI solutions for clinical laboratories.
Reported by Wouter Bulten